The FDA Just Approved This Company’s Alzheimer’s Treatment

finviz dynamic chart for  BIIB

Biogen (BIIB) is an American multinational biotechnology company that specializes in developing treatments for neurological diseases.

And similar to Novo Nordisk, BIIB recently released a groundbreaking drug that could fundamentally alter how medical professionals and families tackle Alzheimer’s moving forward. 

After years of studies, the firm's Alzheimer’s treatment Aduhelm showed that it could effectively slow the cognitive decline of the neurological disease by disrupting the development of amyloid beta plaque in patients.  

As a result, the U.S. Food and Drug Administration (FDA) approved its first Alzheimer’s treatment in over 20 years… And may even be the first truly “effective” therapy to slow Alzheimer’s progression.

This has many investors watching the company forecasting the drug could see sales of $63 million in 2021 alone.

Next year, Wall Street noted that number could surge to $603 million. And by 2023, they could rise above $1.6 billion… potentially surging much higher in the decade ahead.

“IMPERIUM:” The No. 1 Investment of the 2020s

Sponsored

Could this odd-looking machine really be the most transformative innovation in history?

Experts are screaming: “YES”! 

Elon Musk calls it “amazing…” 

A former Apple CEO says: “[It will] have a far bigger impact on humanity than the Internet.” 

While a Harvard Ph.D. says it could “[surpass] the space, atomic, and electronic revolutions in its significance.” 

It’s a technology I call “Imperium.” And it’s about to spark the biggest investment mega trend in history … with one small Silicon Valley company at the center of it all.   

To get all the details, click here now…